USPTO Examiner DAVIS BRIAN J - Art Unit 1614

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19214778METHOD OF TREATING CANCER USING A ZrO2@CaSiO3@g-C3N4 NANOCOMPOSITE MATERIALMay 2025July 2025Allow200NoNo
192025013-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the SameMay 2025September 2025Allow410NoNo
19174523ANTICANCER AGENTS COMPRISING A g-C3N4@CuO/MgAl2O4 NANOHYBRIDApril 2025July 2025Allow310NoNo
19064093INHIBITION OF CANCER CELL VIABILITYFebruary 2025April 2025Allow210NoNo
18976761COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOFDecember 2024April 2025Allow410YesNo
18952635COATED ZEOLITIC IMIDAZOLATE FRAMEWORK (ZIF-8) AS AN EFFICIENT CARRIER FOR THE CYCLOHEPTYLAMINE HYDROCHLORIDE FOR THE TREATMENT OF DIABETESNovember 2024September 2025Allow1020NoNo
18948050CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USENovember 2024March 2025Allow410NoNo
18923620ANTI-AGING PREPARATION FOR SKIN AND APPLICATION THEREOFOctober 2024January 2025Allow310NoNo
18668526METHOD TO SELECTIVELY PRODUCE BENZALANILINE FROM A SCHIFF-BASE REACTION INVOLVING ANILINE AND BENZALDEHYDEMay 2024February 2025Allow920NoNo
18669214LIPIDS AND LIPID NANOPARTICLE FORMULATIONSMay 2024October 2024Allow501NoNo
18659997COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEAMay 2024November 2025Abandon1801NoNo
18648426TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIBApril 2024March 2025Allow1020NoNo
18647511METHODS AND COMPOSITIONS FOR TREATING CANCERApril 2024April 2025Allow1220YesNo
18637083INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTSApril 2024April 2025Allow1210NoNo
18632908PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUSApril 2024December 2025Allow2021NoNo
18630283METHODS OF TREATING MALIGNANT LYMPHOPROLIFERATIVE DISORDERSApril 2024November 2025Abandon1910NoNo
18624670TREATMENTS WITH NIROGACESTATApril 2024October 2024Allow620NoNo
18618110SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORSMarch 2024February 2025Allow1121NoNo
18617058LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONSMarch 2024December 2025Allow2111NoNo
18594898MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONEMarch 2024July 2025Allow1620NoNo
18581307SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USEFebruary 2024April 2025Allow1411NoNo
18439677FABRICATION OF NOVEL NANO-SIZED [4{3,4-BIS-[(5-BROMO-2-HYDROXY-BENZYLIDENE)-AMINO]-PHENYL}-PHENYL-METHANONE] RU(III) COMPLEX FOR PHARMACEUTICAL APPLICATIONSFebruary 2024August 2024Allow610NoNo
18417750COMPOSITIONS COMPRISING AN UROLITHIN COMPOUNDJanuary 2024January 2025Allow1210NoNo
18414185TREATMENTS WITH NIROGACESTATJanuary 2024August 2024Allow710NoNo
18399875FOAM TREATMENT METHOD FOR BACTERIADecember 2023January 2026Allow2520NoNo
18570072ULTRASOUND-RESPONSIVE LIPOSOME NANOPARTICLES AND PREPARATION METHOD AND USE THEREOFDecember 2023December 2025Allow2410NoNo
18538562METHODS OF INACTIVATION OF VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVESDecember 2023March 2025Abandon1510NoNo
18567972Treatment for Down Syndrome-Related Accelerated AgingDecember 2023March 2026Allow2710NoNo
18565865MEANS AND METHODS FOR IMPROVING ANTI-TUMORAL EFFICACY OF TRANSMEMBRANE CHANNEL PROTEIN BLOCKERSNovember 2023February 2026Allow2610NoNo
18289738A PLURALITY OF TASQUINIMOD PARTICLES AND USE THEREOFNovember 2023September 2025Allow2300NoNo
18386906CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USENovember 2023March 2025Allow1620NoNo
18498542ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCEROctober 2023January 2025Allow1520NoNo
18287446IMMUNOSTIMULATORY TOLL-LIKE RECEPTOR AGONIST-NANOPARTICLE FOR CANCER IMMUNOTHERAPYOctober 2023March 2026Allow2920NoNo
18470182COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE ASSOCIATED INFLAMMATION AND DISORDERSSeptember 2023November 2024Allow1420NoNo
18464965METHODS OF TREATING CHRONIC INFLAMMATORY DISEASESSeptember 2023December 2025Allow2720NoNo
18460047INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR)September 2023December 2024Abandon1510NoNo
18238905Series of Skin-Whitening (Lightening) CompoundsAugust 2023October 2024Allow1310NoNo
18237140BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASESAugust 2023August 2024Allow1210NoNo
18277652NITRIC OXIDE-SENSITIVE HYDROGELAugust 2023November 2025Allow2710NoNo
18362789CATIONIC LIPIDS AND TRANSFECTION METHODSJuly 2023April 2025Allow2120NoNo
18358998SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORSJuly 2023June 2024Allow1110NoNo
18215257MINOCYCLINE COMPOUNDS FOR BIODEFENSEJune 2023January 2025Abandon1810NoNo
18340978SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOFJune 2023November 2025Allow2811NoNo
18315404METHODS OF TREATING HEMATOLOGICAL MALIGNANCIES USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONMay 2023August 2024Allow1510NoNo
18315041CAPSID INHIBITORS FOR THE PREVENTION OF HIVMay 2023October 2024Abandon1710NoNo
18314442METHODS OF TREATING CHRONIC INFLAMMATORY DISEASESMay 2023July 2024Allow1410NoNo
182979743-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the SameApril 2023February 2025Allow2220YesNo
18297134CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTORApril 2023October 2024Allow1920NoNo
18188706METHOD FOR TREATING CANCERMarch 2023January 2025Abandon2210NoNo
18124959GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT PANCREATIC CANCERMarch 2023April 2025Allow2510NoNo
18117075METHODS OF TREATING CANCER WITH AN FGFR INHIBITORMarch 2023May 2024Allow1520NoNo
18103410Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorideJanuary 2023January 2026Abandon3510NoNo
18007166OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOFJanuary 2023February 2026Abandon3610NoNo
18018079COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUNDJanuary 2023February 2026Abandon3610NoNo
18006261COMPOUNDS USEFUL AS FACTOR XIA INHIBITORSJanuary 2023October 2025Allow3310NoNo
17999557TRIAZOLONE COMPOUNDJanuary 2023December 2025Allow3711YesNo
18016819COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATIONJanuary 2023February 2026Abandon3710NoNo
18005754HYDROCARBYL-MODIFIED METHYLALUMINOXANE COCATALYSTS FOR BIS-PHENYLPHENOXY METAL-LIGAND COMPLEXESJanuary 2023December 2025Allow3510YesNo
18005159CRYSTALLINE FORM OF HYDROCHLORIDE SALT OF QUINOLINE DERIVATIVEJanuary 2023October 2025Allow3310NoNo
18015691KRAS G12D INHIBITORSJanuary 2023March 2026Allow3830NoNo
18093599TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASESJanuary 2023December 2025Allow3620NoNo
18014143HETEROCYCLIC COMPOUND AND USE THEREOFDecember 2022February 2026Allow3811NoNo
18067975NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOFDecember 2022March 2025Allow2701NoNo
18010604METHOD FOR PROMOTING COLLAGEN PRODUCTIONDecember 2022January 2026Allow3720NoNo
18008873SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAMEDecember 2022December 2025Abandon3601NoNo
17999723PREVENTION OF MCPD FORMATION BY HIGH TEMPERATURE WASHINGNovember 2022October 2025Allow3510NoNo
18057724ANTIBACTERIAL HYDROPHILIC COMPOUNDNovember 2022June 2025Abandon3111NoNo
17998957MACROCYCLIC 7-PYRAZOL-5-YL-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1November 2022December 2025Abandon3610NoNo
17924601Methods of Treating Bone Marrow Failure Syndromes and Compositions for Use in the SameNovember 2022July 2025Allow3210NoNo
17778298CARBALYSOPHOSPHATIDIC ACIDNovember 2022May 2025Allow3600NoNo
17924261METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVENovember 2022September 2025Allow3510NoNo
17921939HETEROCYCLIC COMPOUNDS AS BET INHIBITORSOctober 2022November 2025Abandon3701NoNo
17961437SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCEROctober 2022February 2026Allow4021NoNo
17937599METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVOOctober 2022March 2025Abandon2911NoNo
17995002CO-ADMINISTRATION OF MIRDAMETINIB AND LIFIRAFENIB FOR USE IN TREATING CANCERSSeptember 2022May 2025Allow3200NoNo
17915101Crystal Form Of Thiofuran Pyridazine Compound, Preparation Method Therefor And Application ThereofSeptember 2022February 2026Abandon4120NoNo
17907151PROCESS SULFONATION OF AMINOETHYLENE SULFONIC ESTER WITH CARBON DIOXIDE ADDITION TO PRODUCE TAURINESeptember 2022September 2025Allow3610NoNo
17946101Benzisoxazole Sulfonamide DerivativesSeptember 2022February 2024Allow1710NoNo
17911788PROCESS FOR CONVERTING BIOSOURCED TRIGLYCERIDES INTO A SINGLE-PHASE COMPOSITION CONTAINING FATTY ACID ESTER AND RELATED USES AS BIOFUEL OR LUBRICANTSeptember 2022September 2025Allow3610NoNo
17905953Novel 3,5-Diaminobenzoic Acid Compound, and PIN1 Inhibitor and Therapeutic Agent for Inflammatory Diseases Using SameSeptember 2022September 2025Allow3710NoNo
17887480Series of Compounds for Treatment of Skin Diseases and Other ConditionsAugust 2022March 2025Allow3121NoNo
17882905COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGYAugust 2022September 2024Allow2620NoNo
17877485PARTICLE-FORM HYBRID-SCALE FIBER MATRIXJuly 2022June 2023Abandon1011NoNo
17809179DISSOLVED C60 AND METHOD OF PRODUCING DISSOLVED C60June 2022August 2025Allow3810NoNo
17757514COMBINATIONSJune 2022October 2025Abandon4010NoNo
17751540BRANCHED MULTI-FUNCTIONAL MACROMONOMERS AND RELATED POLYMERS AND USES THEREOFMay 2022August 2024Allow2610NoNo
17750262COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF USING THE SAMEMay 2022January 2024Allow2020NoNo
17775402LEFT-HANDED BICYCLIC MORPHOLINE AND SALT THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USEMay 2022January 2026Allow4520YesNo
17775242TREATING LIVER DISORDERSMay 2022December 2025Abandon4310NoNo
17774583CANCER TREATMENTS TARGETING CANCER STEM CELLSMay 2022December 2025Allow4311NoNo
17772264LIVER TARGETING DRUG, PHARMACEUTICAL COMPOSITION AND USE THEREOFApril 2022August 2025Allow4011NoNo
17770515METHODS OF TREATING, AMELIORATING, AND/OR PREVENTING CANCER USING PYRVINIUM COMPOSITIONSApril 2022July 2025Allow3810NoNo
17714268SOLID STATE FORMS OF RELUGOLIXApril 2022June 2025Allow3910NoNo
17762713CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOFMarch 2022July 2025Allow4010NoNo
17695767CXCL10 InhibitorsMarch 2022November 2024Abandon3221NoNo
17637450BILE ACID DERIVATIVE, COMPOSITION AND APPLICATION THEREOFFebruary 2022July 2025Allow4111NoNo
17636276COMPOUNDS AND COMPOSITIONS FOR TREATING KIDNEY DISEASEFebruary 2022August 2025Abandon4201NoNo
17670078ALCOHOL-RESISTANT DRUG FORMULATIONSFebruary 2022June 2025Allow4021NoNo
17630124PYRROLOPYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINEJanuary 2022April 2025Allow3910NoNo
17628017CARBAMATE-SUBSTITUTED STYRYL SULFONE COMPOUNDS, PREPARATION METHOD AND USE THEREOFJanuary 2022May 2025Allow4011NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAVIS, BRIAN J.

Strategic Value of Filing an Appeal

Total Appeal Filings
10
Allowed After Appeal Filing
6
(60.0%)
Not Allowed After Appeal Filing
4
(40.0%)
Filing Benefit Percentile
88.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 60.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner DAVIS, BRIAN J - Prosecution Strategy Guide

Executive Summary

Examiner DAVIS, BRIAN J works in Art Unit 1614 and has examined 243 patent applications in our dataset. With an allowance rate of 94.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 20 months.

Allowance Patterns

Examiner DAVIS, BRIAN J's allowance rate of 94.7% places them in the 83% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by DAVIS, BRIAN J receive 1.33 office actions before reaching final disposition. This places the examiner in the 19% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DAVIS, BRIAN J is 20 months. This places the examiner in the 92% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +6.2% benefit to allowance rate for applications examined by DAVIS, BRIAN J. This interview benefit is in the 33% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 34.2% of applications are subsequently allowed. This success rate is in the 75% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 68.9% of cases where such amendments are filed. This entry rate is in the 91% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 36.0% are granted (fully or in part). This grant rate is in the 24% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 17.3% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.2% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.